← Back to patent-cliff list
RVP-001
Tier C — Watch / tradeRVP-001
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
In vivo diagnostic
Type
Targets：Updating
Indications (approved)：von Hippel-Lindau syndrome, Multiple sclerosis, Glioma, 脑癌, Meningioma, Brain metastases, Schwannoma, 神经纤维瘤
Regional status
US
Phase II
2024-08-15
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of RVP-001?
Approved indications include: von Hippel-Lindau syndrome, Multiple sclerosis, Glioma, 脑癌, Meningioma, Brain metastases, Schwannoma, 神经纤维瘤.
When does the RVP-001 patent expire?
No public expiry year is available for RVP-001 yet; this page updates once verified.
How do I get a quote for RVP-001 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01